- Home
- ASA vs ALLO Comparison
ASA vs ALLO Comparison
Compare ASA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- ALLO
- Stock Information
- Founded
- ASA 1958
- ALLO 2017
- Country
- ASA United States
- ALLO United States
- Employees
- ASA N/A
- ALLO N/A
- Industry
- ASA Precious Metals
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASA Industrials
- ALLO Health Care
- Exchange
- ASA Nasdaq
- ALLO Nasdaq
- Market Cap
- ASA 415.9M
- ALLO 338.9M
- IPO Year
- ASA N/A
- ALLO 2018
- Fundamental
- Price
- ASA $29.06
- ALLO $1.37
- Analyst Decision
- ASA
- ALLO Strong Buy
- Analyst Count
- ASA 0
- ALLO 10
- Target Price
- ASA N/A
- ALLO $9.66
- AVG Volume (30 Days)
- ASA 52.8K
- ALLO 3.3M
- Earning Date
- ASA 04-08-2025
- ALLO 03-13-2025
- Dividend Yield
- ASA 0.13%
- ALLO N/A
- EPS Growth
- ASA 1102.63
- ALLO N/A
- EPS
- ASA 6.06
- ALLO N/A
- Revenue
- ASA $2,140,037.00
- ALLO $22,000.00
- Revenue This Year
- ASA N/A
- ALLO $110.82
- Revenue Next Year
- ASA N/A
- ALLO N/A
- P/E Ratio
- ASA $4.95
- ALLO N/A
- Revenue Growth
- ASA N/A
- ALLO N/A
- 52 Week Low
- ASA $15.35
- ALLO $1.31
- 52 Week High
- ASA $30.98
- ALLO $4.30
- Technical
- Relative Strength Index (RSI)
- ASA 72.03
- ALLO 34.61
- Support Level
- ASA $26.93
- ALLO $1.49
- Resistance Level
- ASA $30.99
- ALLO $1.69
- Average True Range (ATR)
- ASA 0.98
- ALLO 0.14
- MACD
- ASA 0.21
- ALLO -0.04
- Stochastic Oscillator
- ASA 85.21
- ALLO 9.86
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.